Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology · Autosomal Dominant Alzheimer Disease

What to Expect: The Timeline of ADAD Progression

At a Glance

In Autosomal Dominant Alzheimer Disease (ADAD), brain changes begin up to 20 years before symptoms appear. This hidden timeline, tracked by Estimated Year of Onset (EYO), allows individuals to anticipate memory and motor symptoms and participate in early prevention trials.

In Autosomal Dominant Alzheimer Disease (ADAD), the journey of the disease is remarkably predictable but often hidden for many years. Unlike the more common form of Alzheimer’s, ADAD follows a clear biological clock that begins decades before a person notices a single memory lapse.

The Invisible Timeline: The Preclinical Phase

One of the most powerful insights from research like the Dominantly Inherited Alzheimer Network (DIAN) is that the brain begins to change long before symptoms appear. Scientists use a metric called Estimated Year of Onset (EYO) to map this. EYO is calculated by subtracting your current age from the age your parent first showed symptoms [1][2].

The biological sequence typically unfolds in this order [3][4]:

  • -20 to -15 Years: Amyloid-beta protein begins to clump into plaques. This is often largely “complete” by the time symptoms start [5][3].
  • -10 Years: Changes in brain connectivity and white matter (the brain’s “wiring”) become detectable. Levels of Neurofilament Light (NfL), a marker of nerve cell damage, begin to rise in the blood [6][7].
  • -5 Years: The brain’s use of glucose (energy) begins to slow down, and tau tangles begin to spread, leading to visible brain shrinkage (atrophy) on an MRI [3][8].
  • Year 0: Clinical symptoms, such as memory loss or personality changes, become apparent to others [2].

Early Symptoms and “The Atypical”

While memory loss is the most common early sign, ADAD often involves “atypical” symptoms that aren’t usually seen in typical late-onset Alzheimer’s. These symptoms occur because the genetic mutations can affect deeper parts of the brain, like the basal ganglia [9].

Cognitive Symptoms

Early signs often include subtle changes in “executive function”—tasks like planning a meal, managing a budget, or following a complex conversation [10]. You might notice a slight “fog” or difficulty multitasking before you notice significant forgetfulness.

Atypical Neurological Symptoms

In ADAD, the disease can also affect the body’s movement. These symptoms occur in about 30% of cases and may include [9][11]:

  • Spastic Paraparesis: A stiffness or weakness in the legs that can make walking difficult. This is particularly common with specific mutations in the PSEN1 gene [11][12].
  • Myoclonus: Brief, involuntary muscle jerks or “twitches” [9].
  • Seizures: People with ADAD have a higher risk of seizures than those with the common form of Alzheimer’s, though these are usually manageable with medication [13].

Progression and Quality of Life

The rate of decline in ADAD is often faster than in late-onset Alzheimer’s [8]. Because the disease starts when a person is younger and physically stronger, the transition over time can feel intense.

However, it is crucial to know that the progression is gradual. Even after symptoms begin at “Year 0,” many individuals maintain their independence, continue to work, and enjoy a high quality of life for several years into the early symptomatic phase. The transition to needing full-time care happens over many years, not overnight [2][14].

Furthermore, knowing your Estimated Year of Onset provides a unique window of opportunity. This lead time allows you to participate in prevention trials that target the disease during that 20-year “hidden” preclinical phase [15][16].

Phase Timeline Key Changes
Preclinical 20 to 5 years before onset Amyloid clumping, rising NfL levels, no symptoms [3][7]
Prodromal 5 years before to Year 0 Subtle planning issues, energy changes in brain [3]
Symptomatic Year 0 onwards Memory loss, potential motor stiffness, gradual decline [2][8]

Common questions in this guide

What is Estimated Year of Onset (EYO) in ADAD?
Estimated Year of Onset (EYO) is a calculation used to predict when a person with ADAD might begin showing symptoms. It is determined by subtracting the age at which your affected parent first showed clinical signs of the disease from your current age.
How long is the preclinical phase in ADAD?
The preclinical phase of ADAD begins 15 to 20 years before noticeable memory loss occurs. During this hidden phase, amyloid plaques and other brain changes slowly develop without causing any outward clinical symptoms.
What are the atypical symptoms of early-onset ADAD?
Unlike typical Alzheimer's, ADAD can cause movement issues in about 30% of cases. These atypical symptoms may include leg stiffness and weakness (spastic paraparesis), sudden muscle twitches (myoclonus), and a higher risk of treatable seizures.
What tests monitor ADAD progression before symptoms start?
Doctors use brain imaging like PET scans and MRI to track amyloid plaque buildup and brain shrinkage. They can also test for biomarkers like Neurofilament Light (NfL), which indicates early nerve cell damage up to 10 years before symptoms start.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How is the 'Estimated Year of Onset' (EYO) being calculated for my specific case?
  2. 2.Are there specific neurological symptoms, such as spasticity or myoclonus, that I should be monitoring for based on my family's mutation?
  3. 3.What does my current biomarker profile (e.g., NfL or amyloid PET) suggest about where I am on the ADAD timeline?
  4. 4.How do you monitor for seizures or other 'atypical' symptoms in ADAD, and what are the management options?
  5. 5.Given my family history, how frequently should I be having cognitive assessments and brain imaging?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred.

    Fuller JT, Cronin-Golomb A, Gatchel JR, et al.

    The journal of prevention of Alzheimer's disease 2019; (6(2)):112-120 doi:10.14283/jpad.2019.6.

    PMID: 30756118
  2. 2

    Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN).

    McKay NS, Gordon BA, Hornbeck RC, et al.

    Nature neuroscience 2023; (26(8)):1449-1460 doi:10.1038/s41593-023-01359-8.

    PMID: 37429916
  3. 3

    Investigating the Aβ and tau pathology in autosomal dominant Alzheimer's disease: insights from hybrid PET/MRI and network mapping.

    Zhou Z, Wang Q, Liu L, et al.

    Alzheimer's research & therapy 2025; (17(1)):45 doi:10.1186/s13195-025-01690-1.

    PMID: 39962560
  4. 4

    Alzheimer's disease associated with Down syndrome: a genetic form of dementia.

    Fortea J, Zaman SH, Hartley S, et al.

    The Lancet. Neurology 2021; (20(11)):930-942 doi:10.1016/S1474-4422(21)00245-3.

    PMID: 34687637
  5. 5

    Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.

    Yau WW, Tudorascu DL, McDade EM, et al.

    The Lancet. Neurology 2015; (14(8)):804-813 doi:10.1016/S1474-4422(15)00135-0.

    PMID: 26139022
  6. 6

    Functional network disruption in cognitively unimpaired autosomal dominant Alzheimer's disease: a magnetoencephalography study.

    van Nifterick AM, de Haan W, Stam CJ, et al.

    Brain communications 2024; (6(6)):fcae423 doi:10.1093/braincomms/fcae423.

    PMID: 39713236
  7. 7

    Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.

    Preische O, Schultz SA, Apel A, et al.

    Nature medicine 2019; (25(2)):277-283 doi:10.1038/s41591-018-0304-3.

    PMID: 30664784
  8. 8

    Earlier Alzheimer's disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading.

    Frontzkowski L, Ewers M, Brendel M, et al.

    Nature communications 2022; (13(1)):4899 doi:10.1038/s41467-022-32592-7.

    PMID: 35987901
  9. 9

    Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.

    Vöglein J, Paumier K, Jucker M, et al.

    Brain : a journal of neurology 2019; (142(5)):1429-1440 doi:10.1093/brain/awz050.

    PMID: 30897203
  10. 10

    Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease.

    Buckles VD, Xiong C, Bateman RJ, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2022; (18(10)):1754-1764 doi:10.1002/alz.12505.

    PMID: 34854530
  11. 11

    Spastic paraplegia preceding PSEN1-related familial Alzheimer's disease.

    Chelban V, Breza M, Szaruga M, et al.

    Alzheimer's & dementia (Amsterdam, Netherlands) 2021; (13(1)):e12186 doi:10.1002/dad2.12186.

    PMID: 33969176
  12. 12

    Activation of γ-Secretase Trimming Activity by Topological Changes of Transmembrane Domain 1 of Presenilin 1.

    Cai T, Yonaga M, Tomita T

    The Journal of neuroscience : the official journal of the Society for Neuroscience 2017; (37(50)):12272-12280 doi:10.1523/JNEUROSCI.1628-17.2017.

    PMID: 29118109
  13. 13

    Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimer's disease.

    Levitis E, Vogel JW, Funck T, et al.

    Brain communications 2022; (4(3)):fcac085 doi:10.1093/braincomms/fcac085.

    PMID: 35602652
  14. 14

    A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease.

    Grill JD, Bateman RJ, Buckles V, et al.

    Alzheimer's research & therapy 2015; (7(1)):50 doi:10.1186/s13195-015-0135-0.

    PMID: 26203303
  15. 15

    Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.

    Rios-Romenets S, Lopera F, Sink KM, et al.

    Alzheimer's & dementia : the journal of the Alzheimer's Association 2020; (16(7)):1023-1030 doi:10.1002/alz.12109.

    PMID: 32418361
  16. 16

    Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease.

    Cash DM, Morgan KE, O'Connor A, et al.

    The journal of prevention of Alzheimer's disease 2025; (12(6)):100133 doi:10.1016/j.tjpad.2025.100133.

    PMID: 40118731

This page explains the ADAD progression timeline for educational purposes only. Always consult your neurologist for personalized medical advice, symptom management, and trial eligibility.

Get notified when new evidence is published on Early-onset autosomal dominant Alzheimer disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.